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tissue sarcomas following radiotherapy (RT). This manuscript, produced by a European
Organisation for Research and Treatment of Cancer e Soft Tissue and Bone Sarcoma Group
(EORTC e STBSG) and Imaging Group endorsed task force, aims to propose standardisa-
tion of magnetic resonance imaging techniques and interpretation after neoadjuvant RT for
routine use and within clinical trials.
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For patients with soft tissue sarcomas (STS) an en-bloc
resection with negative margins will usually provide
long-term local control in several patients even without
preoperative or postoperative radiotherapy (RT) [1].
However for the management of the more aggressive
STS subtypes (especially of intermediate to high grade
histology, larger than 5 cm and/or deep seated), surgery
alone results in inferior local control rates as compared
to surgery in combination with RT [2]. Historically but
also based upon the Canadian SR-2 trial [3], for pre-
operative RT, a conventionally fractionated RT regimen
of once-daily 1.8e2 Gy up to a total dose of 50e50.4 Gy
over 5 weeks is chosen. The absence of a standardised
approach to response assessment in this setting impacts
not only clinical practice but also clinical trials investi-
gating novel RT delivery. Regimens applying both
hyperfractionation (smaller fraction doses usually pre-
scribed twice daily) and hypofractionation (greater than
2 Gy per fraction [4e6]) are under investigation. Also, in
an attempt to sensitise sarcoma cells and/or sarcoma
stroma to radiation, chemotherapy and targeted agents
are being applied concurrently with RT, such as antra-
cycline/ifosfamide [7,8], bevacizumab [9], sorafenib
[10,11], sunitinib [12], pazopanib [13] and more recently
nanoparticles [14]. In order to appreciate the true value
of these new regimens a standardised and reproducible
radiological evaluation is critical.
This manuscript which focuses on the use of magnetic
resonance imaging (MRI) for assessing response in STS
following RT is targeted at radiologists and clinical
oncologists but will serve as a guide to all health pro-
fessionals in the STS community.
2. Imaging objectives
In an era of evolving targeted RT techniques such as
intensity modulated RT and image guided RT, imaging
is crucial for achieving accurate treatment volumes with
sparing of adjacent normal tissues at risk of toxicity.
STS are notorious for their marked inter- and intra-
tumoural heterogeneity and some investigators are
already starting to interrogate the clinical value of “dosepainting” regimens where non-uniform radiation is
distributed based on functional or molecular imaging
[15]. RT planning is not within the remit of this article,
however the MRI protocol before and after RT should
be identical and performed on the same MRI scanner.
Following RT, imaging can be used not only to assess
response but also to revisit surgical staging as increases
in tumour size secondary to oedema, haemorrhage and
necrosis are not uncommon [16] although this does not
influence local control rates [17].
2.1. Timing of post RT MRI studies
Currently imaging during and immediately post RT
should be avoided as the complex imaging features in
this setting can be misleading (Fig. 1). Imaging should
be performed as close to the surgical date as possible
and most clinical protocols assume that an interval for
surgery of 4e6 weeks following RT is optimal.
2.2. Routine MRI protocol
For limb sarcomas a combination of T2-weighted (W),
T1-W, T1-W with fat saturation, T1-W fat-saturated (FS)
contrast-enhanced and short-tau inversion recovery
(STIR) should be used (Fig. 2). Some institutions may
choose to use T2with fat saturation orDixon water T2-W
in preference to STIR. These sequences can be supple-
mented by diffusion weighted MRI (DWI) sequences (b
50, 600 and 900 s/mm2) and apparent diffusion coefficient
(ADC) maps depending on local expertise. Coverage
should include the joint above and below the sarcoma.
Choice of imaging for truncal STS is site dependent but a
similar MRI protocol can be used for masses in the
anterior abdominal wall for example. Imaging may be
performed either at 1.5T or 3T. At other sites such as the
mediastinum, contrast enhanced computed tomography
(CT) can bemore suitable since CT is less prone tomotion
artefacts. For retroperitoneal sarcomas most centres use
CT but the MRI protocols used for limb sarcomas can
easily be translated to the retroperitoneum. This can be
particularly helpful to address targeted questions
regarding local invasion to structures such as psoas,
neural foramina and bone and will become increasingly
Fig. 1. Pseudoprogression post radiotherapy. Contrast enhanced T1-W MRI with fat saturation of an anterior compartment pleomorphic
sarcoma before (a), 6 weeks following radiotherapy (b) and 10 weeks following radiotherapy (c). At 6 weeks post radiotherapy (b) the
increase in size and enhancement gives a false positive for tumour progression. Surgery was delayed for medical reasons and MRI at 10
weeks confirms tumour regression. Five to 10% viable tumour was present in the resection specimen.
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toneal sarcomas increases. Careful attention should be
made to ensure reproducible patient positioning and to
avoid deforming the contours of the tumour i.e. patients
with buttock tumours should be imaged prone.
2.3. Assessing response
Histopathological changes including necrosis, cystic
change, haemorrhage, hyalinisation and fibrosis whichFig. 2. Recommended clinicalMRI protocol. Axial T1-W (a), T2-W (b), T
b50 (f), b900 (g), ADCmap (h). Note that formorphological imaging bo
are included.occur following RT may influence dimension based as-
sessments of response significantly. In fact with the
exception of myxoid liposarcomas [18] (Fig. 3) signifi-
cant dimensional radiologic responses after preoperative
RT are rare events and have been reported as low as 0%
[19]. Miki et al [20] showed that 31% of tumours
increased in size by more than 10% but this was not
associated with a deterioration in local recurrence free
survival, event free survival or overall survival. Look
et al [16] failed to show any correlation with Response1 fat saturated (FS) (c), T1 FSþ contrast (d); coronal STIR (e); DWI
th limbs are included but DWI suffers extreme artefacts if both limbs
Fig. 3. Myxoid liposarcoma in the anterior compartment of the left thigh shows marked reduction in size 6 weeks following RT. T2-W (a)
and T1-W fat saturated (FS) post contrast (b) before RT and T2-W (c) T1 FS post contrast (d) 6 weeks following RT.
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outcome measures and demonstrated that tumours
could show significant reductions in size despite
demonstrating predominantly viable tumour whereas
stable or growing tumours could show dramatic histo-
pathological response. In fact growing tumours have
been shown to have a higher incidence of mosaic high
and low T2 signal changes on MRI compared to tu-
mours with stable or reducing size which correlated with
cystic change and haemorrhage, respectively on histo-
pathology [20]. Le Grange [17] reported that RECIST
was also a poor reflection in overall changes in tumour
volume classifying 89% of tumours as stable disease
despite 80% of tumours reducing in volume.
The most reliable measure of tumour response to pre-
operative RT in STS has not yet been determined. Efforts
should be directed towards distinguishing non-viable el-
ements from visible tumour and new surrogate end-points
for pathological response should be defined. Such an
approach has already been taken for gastrointestinal
stromal tumours where Choi criteria incorporate tumour
attenuation changes as well as size [21]. The pilot study by
Stacchiotti et al [22] has provided preliminary evidence
that this may also be useful in a post chemoradiotherapy
setting for STS. However in synovial sarcoma they were
not able to differentiate the cystic component of tumour
from treatment effect. In such cases functional imaging
techniques may provide additional information. A small
study of fluorodeoxyglucose (FDG) positron-emission
tomography/CT in high-grade sarcomas confirmed the
inability of CT volumetric measurements to identify his-
topathological responders but did show some promise for
FDG uptake measurements of standardised uptake value
(SUV) max and SUV mean [23].
It is important to recognise that in current clinical
practice in the absence of metastatic disease, appearanceson post RT imaging are unlikely to alter the decision to
operate. Furthermore, neoadjuvant RT is very unlikely
to render an inoperable STS resectable [24]. This imaging
primarily serves to guide operative management partic-
ularly in cases where the STS has increased in size.
However recommended guidelines for response assess-
ment of STS to RT in routine clinical practice include:
1. Post RT imaging should not be performed earlier than 4
weeks post RT (later if possible).
2. Images acquired in the same plane should be performed
with identical planning and slice thickness to allow corre-
lation between sequences.
3. With the exception of myxoid liposarcomas, size and vol-
ume measurements should not be used to reflect histo-
pathological response.
4. Internal signal/density characteristics should be used in
combination to assess response. For example diminished
enhancement and reduction in size of restricted components/
rising ADC on DWI may be interpreted as response (Fig. 4).
5. Areas of new enhancement should be interpreted with
caution as this can arise secondary to vascular disruption
following RT and does not necessarily reflect progression.
6. Not all areas of diminished enhancement following RT
represent necrosis and therefore attention to terminology is
suggested. The term ‘treatment effects’ may be more
appropriate encompassing several processes including ne-
crosis, cystic change (liquefaction), hyalinisation etc.
For clinical trials where novel regimens are under
interrogation quantitative measures may be desirable
and this will be discussed in the following section.
2.4. Functional imaging and response assessment in
clinical trials
As discussed previously dimensional assessments of
response are not appropriate in this setting. In other
Fig. 4. Axial MRI of a pleomorphic sarcoma in the anterior compartment of the left thigh. T2-W, T1-W fat saturated post contrast, b900
DWI and ADC map pre (aed) and 6 weeks post radiotherapy (eeh). Post radiotherapy images show a small decrease in size but more
impressive reduction in enhancement with diminished areas of restricted diffusion (arrows) on b900 DWI and ADC map.
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to neoadjuvant management of STS. STS can be use-
fully interrogated by multiparametric MRI but both
intertumoural and intratumoural heterogeneity can
mask treatment effects if data are analysed for cohort
effects. It seems reasonable to expect that different sar-
coma subtypes may behave differently and therefore
subgroup analysis is strongly recommended. Repeat-
ability and reproducibility of different functional MRI
parameters is also profoundly influential and therefore
for quantitative studies the ideal and most robust
approach is for each patient to undergo two baseline
studies thereby defining their own repeatability [25e29].
This is also an approach which can be used in multi-
center trials as repeatability is a critical factor influ-
encing the decision to pool data although this does of
course have resource and time implications. Repeat-
ability studies are also important for future proofing
data for post hoc analysis, which is particularly impor-
tant for rare tumour types where data is scarce.
Although the proposed link between ADC derived
from DW MRI and cellularity makes this arguably the
most promising parameter it is important to remember
that it is likely to be influenced by many factors
including water motion in different compartments,
microarchitecture and heterogeneity, membrane integ-
rity, presence of macromolecules leading to water
binding, the cellular volume fraction, active transport as
well as the MRI acquisition parameters and differences
in MRI scanner hardware. Although there is paucity of
sarcoma specific data it remains important to notice that
the inverse correlation between cell density in soft tissues
and ADC has not been so impressive in all cell types
[30,31]. It is likely therefore that ADC is a complex
function of tissue microarchitecture which is influencedby several components. A significant advantage of ADC
is speed of acquisition and good reproducibility with a
reported coefficient of variation of 4.8% in one patient
study [32] and slightly greater in volunteer studies of
different organs with CVs ranging from 7 to 16.9%
outside of the liver [33]. Choice of b values has been
shown to influence ADC in several tissues [34,35].
Consensus recommendations for DW-MRI as a cancer
biomarker recommend that protocols should be opti-
mised to maximise signal-to-noise ratio, minimise arte-
facts from ghosting and distortion, optimise fat
suppression, ensure ADC values can be measured
accurately and reproducibly and, ideally, use parameters
which can be replicated on other platforms [27]. How-
ever development of protocols for multicenter studies
necessitates additional trade-offs between optimisation
and standardisation of protocols on different platforms.
Some parameters are difficult or impossible to stan-
dardise such as diffusion gradient scheme, diffusion
gradient strengths and timings, and methods of fat
suppression and parallel imaging. It is not possible to
standardise the method of fat suppression across scan-
ners from different manufacturers although spectral
methods may be employed on all scanners. Spectral
methods may be preferable over inversion recovery as
the latter reduces the overall signal and introduces T1
weighting. However STIR may be advantageous where
B0 homogeneity is poor.
It is likely that for any multicenter imaging study, a
lead site will be nominated. It is the responsibility of this
site to disseminate a final protocol, taking into account
the capabilities of scanner types and field strengths at
participating sites. Sites should agree on aspects of the
protocol that should be fixed e.g. slice thickness, orien-
tations, b-values for DWI, TEs for R2*. Some aspects
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ages are optimised from all scanners e.g. diffusion
encoding gradient schemes (monopolar versus double
spin-echo). The process of producing the final protocol
for a study will require development work and the
challenges of this may depend on the scanners involved
and the anatomy being imaged. This also includes
defining what common elements are possible. It is
important that this process should be built into the
schedule and budget of a study as this is too often over
looked.
Donati et al [33] have addressed the questions sur-
rounding the use of different field strengths and vendor
platforms in DWI multicenter studies. Critically they
found no significant difference between ADCs at
different field strengths but they did find that vendor
variability had greater influence at 3T. Additionally the
findings of the Innovative Medicines Initiative QuIC-
ConCePT (Quantitative Imaging in cancer: Connecting
cellular Processes with Therapy) project are eagerly
awaited. This aims to qualify imaging biomarkers
including DW MRI and a standardisation procedure of
diffusion MRI is being established in collaboration be-
tween QuIC-ConCePT in Europe and QIBA (quantita-
tive imaging biomarker association) in the United
States.
Ice-water phantoms containing water or sucrose so-
lutions have previously been used to compare ADC es-
timates between scanners [36,37]. Ice-water provides a
simple and inexpensive method to control temperature.
Sucrose restricts diffusion of water molecules and can be
used to reduce the ADC of water to values comparable
to ADCs observed in vivo. Phantoms containing sucrose
solutions have also been used to assess long-term
repeatability of ADC estimates [38]. The use of a large
Field of View (FOV) imposes an additional requirement
for good homogeneity of ADC estimates across the
FOV in addition to accurate ADC estimates near the
isocentre. Although phantoms are likely to have an
important role in multicenter studies they are unlikely to
replace the usefulness of repeatability studies in subjects.
It has become apparent that ADC is influenced also
by perfusion effects at low b values, which can be
interrogated by more sophisticated non-
monoexponential models such as intravoxel incoherent
motion (IVIM) and stretched exponential [39]. However
our understanding of the physiology which underpins
these measurements is limited.
Although experience of ADC metrics in other tu-
mours is now quite advanced, the presence of lipid and
myxoid elements in many STS will mean that the most
sensitive metrics will have to be redefined. The role of
diffusion weighted imaging in assessing response to RT
in STS is yet to be fully explored. Prospective studies
with histopathological correlation and outcome data are
much needed.Other options for exploring tumour vascularity
include enhancing fraction or more formal measures of
perfusion from dynamic contrast enhanced MRI (DCE-
MRI) such as Ktrans which is thought to reflect micro-
vascular permeability. These have intrapatient co-
efficients of variation of 8.6% and 13.9%, respectively
[26]. A major advantage of enhancing fraction over
DCE MRI is whole tumour coverage in the case of large
tumours. R2* measures of hypoxia from blood oxygen
level dependent (BOLD) MRI are becoming increas-
ingly relevant as hypoxia is a key mechanism leading to
radioresistance. Hypoxia mapping techniques therefore
have great potential for improving dose delivery [40]. In
preclinical fibrosarcoma models R2* studies provided a
completely non-invasive prognostic indicator of radio-
therapeutic response but reproducibility in the clinical
studies is not well defined [41]. Recommended parame-
ters for reporting in clinical trials are listed as follows:
2.5. Recommended parameters for reporting
multiparametric MRI in clinical trials (optional
parameters in italics)
Maximum axial dimension (mm)
Tumour volume (mm3)
ADC: mean, median, (10th, 25th, 75th, 90th percen-
tiles, skew and kurtosis.)
Contrast enhanced MRI: enhancing fraction
þ/ Ktrans, iAUC60, Kep, Ve, Vp.
Non-monoexponential models for example D, f and D*
from IVIM.
BOLD: R2*
For other soft tissue tumours either high b value
DWI images or contrast-enhanced images are most
often selected for drawing regions of interest (ROIs).
However for STS elements such as fat and myxoid
components may not be identifiable on such sequences
and therefore T2-W sequences may be more appropriate
for drawing ROIs with use of other sequences for
correlation.
Although multiparametric MRI is extremely prom-
ising currently data analysis times are prohibitive.
Drawing ROIs on image slices through the whole
tumour volume at multiple time points, in addition to
post processing and data analysis is time consuming.
Advances in data informatics and workflow design are
much needed to enable translation of these technologies
from small to larger scale use.
Until further validation studies are available, use of
multiparametric MRI in clinical trials should be regar-
ded as exploratory. The majority of planned and current
neoadjuvant studies have the benefit of resection speci-
mens which can be used for histopathological assess-
ment of response as primary or secondary outcome
measures along with progression free survival or overall
survival.
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clinical trials
1.5T is preferable for planning multicentre studies. 3T is
possible but greater vendor variability should be
considered.
Subgroup analysis of broad histopathological sub-
types is recommended where possible.
The MRI protocol should include clinical sequences
supplemented with DWI and quantitative contrast
enhanced MRI (enhancing fraction þ/DCEMRI with
high temporal resolution of at least 3 s). Non-mono-
exponential DWI models and BOLD MRI are inter-
esting but optional.
Coverage should include the entire tumour. For large
tumours this is not possible for all sequences such as
DCE MRI and BOLD but in such circumstances at least
three slices of data should be acquired and analysed.
Ideally repeatability should be established using two
baseline studies for each patient performed within 7
days of each other. This is feasible for non contrast
enhanced components such as DW MRI and BOLD
however the invasive nature of DCE MRI will usually
preclude this.
ROIs should be drawn throughout the whole tumour
volume on T2-W images with use of other sequences for
visual correlation.
Recommended b values for DWI are 50, 600, 900 s/
mm2 with spectral fat saturation techniques.
Recommended b values for non-monoexponential
models of DWI are 0, 25, 50, 80, 150, 300, 500, and
800 s/mm2.
Recommended TEs for BOLD: 5, 10, 30, 45, and
55 ms
3. Discussion
Here, to the best of our knowledge for the first time in
the literature, a systematic process for MRI of
STS following neoadjuvant RT is described. To date,
radiological series post RT have used heterogeneous
methodology, which makes comparisons extremely
challenging.
The next research strategy will be to correlate the
imaging characteristics after completion of neoadjuvant
management of STS with pathological phenomena in
the definitive resection specimen and also with local
control rates and overall survival. Until such a time,
functional imaging in clinical trials of STS should be
regarded as exploratory. This should take place within
prospective studies, using double baseline and optimised
MR protocols with broad stratification of sarcoma
subtypes. Power calculations to determine the number
of patients should make use of repeatability data from
dual baseline and effect size measured in pilot studies.
Whole volume coverage may be difficult to achieve inlarge tumours and it may be necessary to adopt pro-
tocols that include whole volume coverage for some
measurements e.g. ADC and local measurements for
some others, e.g. R2*. Once the pathological data can be
reliably predicted by preoperative imaging, the sarcoma
scientific community can start to implement these read-
outs in individual patient care. Hopefully in the future,
all these investigations and techniques, can guide us
either to stop an ineffective neoadjuvant therapy if so
designated, or to de-intensify a regimen in case of shown
efficacy on-treatment, in an attempt to decrease both
postoperative morbidity and long term sequellae.
For this purpose, this multidisciplinary task force,
came to consensus on MRI evaluation of response after
neoadjuvant RT in STS.
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